Clinical Trial Update: Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

This Phase 2 neoadjuvant trial evaluated FEC followed by weekly paclitaxel and trastuzumab in HER2-positive breast cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Epirubicin (epirubicin)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Lucia Del Mastro,MD | Conditions: HER-2 Positive Breast Cancer | Phase 2 | Status: COMPLETED